Celltrion

Apr 08, 2019

Celltrion Partners with the Canadian Biotech Company, iProgen Biotech to Develop a Series of Novel ADCs

Nov 29, 2018

Celltrion and Teva Announce FDA Approval of TRUXIMA® (rituximab-abbs), a Biosimilar to RITUXAN®, for Three Non-Hodgkin’s Lymphoma Indications

Nov 28, 2018

FDA approves first biosimilar for treatment of adult patients with non-Hodgkin's lymphoma

Sep 26, 2017

Celltrion taps Oracle Health Sciences Safety Solutions to Help Bring Cost-Effective Life-Saving and Biosimilar Drugs to Market